Hemostasis and coagulation analyzers are medical devices used to test blood
coagulation and help in detecting blood clotting disorders. These analyzers
perform various tests such as prothrombin time (PT), activated partial
thromboplastin time (APTT), fibrinogen, and thrombin time tests. They help
physicians in monitoring anticoagulant therapy and assist in preventing
life-threatening blood loss during surgeries. The growing prevalence of blood
clotting disorders such as deep vein thrombosis and pulmonary embolism is
driving the demand for hemostasis and coagulation analyzers globally.
The Global Hemostasis/ Coagulation Analyzer Market is estimated to be valued at US$ 6.47 Bn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period
2024 to 2031.
Key Takeaways
Key players operating in the Hemostasis/
Coagulation Analyzer Market Growth are Horiba Medical, Siemens
Healthineers AG, Agappe Diagnostics Ltd, NIHON KOHDEN CORPORATION, Sysmex
Corporation, F. Hoffmann-La Roche Ltd, Stago Group, Maccura Biotechnology Co.,
Ltd., Thermo Fisher Scientific Inc., Haemonetics Corporation, Genrui Biotech
Co., Ltd., BIOLABO S.A.S, Erba Mannheim, Sclavo Diagnostics International, and
Helena Laboratories Corporation. These players are focusing on new product
launches and enabling technologies to gain a competitive edge in the market.
The growing incidence of cardiovascular diseases, trauma injuries,
transplantation surgeries, and increasing geriatric population and obesity
rates are anticipated to generate more demand for coagulation testing. This
presents lucrative opportunities for players in the hemostasis and coagulation
analyzer market to expand their offerings and penetrate untapped markets.
Major players are strategizing global expansion plans by strengthening their
distribution networks across developed and emerging countries. For instance,
Sysmex formed cooperation with Maruho for hemostasis analyzers sales and
support in 50 countries across the Middle East, Africa, and Asia. In addition,
companies are gaining approvals to market their analyzers in different
geographic regions, which will further support global market growth over the
forecast period.
Market drivers:
- Growing incidence of blood disorders: The rising global prevalence of blood
disorders like deep vein thrombosis and pulmonary embolism due to sedentary
lifestyle is a key driver for the market.
- Increasing surgical procedures: Growing number of surgeries lead to use of
hemostasis testing for blood clotting, thereby driving market growth.
Market restraints:
- High capital investment: Hemostasis analyzers require huge capital
investments and infrastructural setup that may restraint its adoption in low
resource settings.
- Stringent regulations: Hemostasis devices are subject to stringent
regulations pertaining to safety, efficacy which increases compliance costs for
manufacturers.
Segment Analysis
The hemostasis and coagulation analyzer market is dominated by the clinical
laboratory segment. Clinical laboratories perform a large number of coagulation
tests to manage patients on anticoagulant therapy and to diagnose bleeding and
clotting disorders. The availability of automated, high-volume coagulation
analyzers suitable for healthcare settings with medium to high testing volumes
favors the growth of this segment.
The point-of-care testing segment is another promising sub-segment in the
market. Point-of-care coagulation testing allows fast test results bedside or
in emergency departments and operating rooms. This helps facilitate timely
clinical decision making. The development of user-friendly portable devices for
near-patient and point-of-care testing is expected to drive the growth of this
segment during the forecast period.
Regional Analysis
North America currently dominates the hemostasis and coagulation analyzer
market due to the high patient awareness levels and ready availability of
automated systems. The Asia Pacific region is expected to witness the highest
growth during the forecast period owing to improving healthcare infrastructure,
rising medical tourism, and increasing adoption of automated analyzers in major
Asian countries. Within the Asia Pacific, China and India are expected to be
the fastest growing markets due to growing geriatric population, rising
healthcare expenditures, and increasing focus of global market players in these
countries. Europe is also expected to exhibit significant growth due to
supportive government initiatives encouraging the adoption of advanced
laboratory medical technologies.
Get More Insights On This Topic: Hemostasis/Coagulation
Analyzer Market